A new NCL-targeting aptamer-drug conjugate as a promising therapy against esophageal cancer
Authors:
Open Access
- 28 January 2025
- journal article
- research article
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 1-23
Abstract
Esophageal cancer (EC) is one of the most common highly malignant tumors of the digestive system, with a poor prognosis under current treatment regimens. Nucleolin (NCL) is overexpressed in many tumors, and drugs specifically targeting NCL may offer a promising strategy for treating esophageal cancer. Here, we designed and prepared a novel aptamer-conjugated drug targeting NCL by AS1411 aptamer-human serum albumin (HSA)-the apoprotein of lidamycin (LDP)-active enediyne chromophore (AE), in order to achieve targeted treatment of esophageal cancer. The experimental results revealed that AS1411-HSA-LDP effectively binds to esophageal cancer cells and could be efficiently internalized by esophageal cancer cells. In the KYSE520 xenograft tumor nude mouse model, AS1411-HSA-LDP could be targeted and enriched in the tumor location for a long time. AS1411-HSA-LDP-AE exhibited a strong cell-killing activity in esophageal cancer cells, inhibited cell migration and invasion, and induced cell apoptosis. The animal studies confirmed that AS1411-HSA-LDP-AE exhibited a strong anti-tumor effect. These findings suggested that the novel NCL-targeting aptamer-drug conjugate constructed based on lidamycin exhibited a strong anti-tumor effect, providing a promising strategy for the targeted treatment of esophageal cancer.Keywords
Funding Information
- the CAMS Innovation Fund for Medical Sciences (2021-1-I2M-026)
- Anhui University of Chinese Medicine Foundation (No. 2023rcZD003)
- the Key Project of Anhui Province Department of Education (No. 2022AH050506)
This publication has 37 references indexed in Scilit:
- Repurposing AS1411 for constructing ANM-PROTACsCell Chemical Biology, 2024
- Development of novel celastrol-ligustrazine hybrids as potent peroxiredoxin 1 inhibitors against lung cancerEuropean Journal of Medicinal Chemistry, 2023
- A Non‐G‐Quadruplex DNA Aptamer Targeting NCL for Diagnosis and Therapy in Bladder CancerAdvanced Healthcare Materials, 2023
- Recent progress of aptamer‒drug conjugates in cancer therapyActa Pharmaceutica Sinica B, 2023
- Fractions of Hoslundia opposita Vahl and hoslundin induced apoptosis in human cancer cells via mitochondrial-dependent reactive oxygen species (ROS) generationBiomedicine & Pharmacotherapy, 2022
- Cancer-associated fibroblasts: An emerging target against esophageal squamous cell carcinomaCancer Letters, 2022
- Comparative genomic analysis of esophageal squamous cell carcinoma and adenocarcinoma: New opportunities towards molecularly targeted therapyActa Pharmaceutica Sinica B, 2021
- Advances and challenges in the treatment of esophageal cancerActa Pharmaceutica Sinica B, 2021
- A novel enediyne‐integrated antibody–drug conjugate shows promising antitumor efficacy against CD30+ lymphomasMolecular Oncology, 2018
- The implications and mechanisms of the extra-nuclear nucleolin in the esophageal squamous cell carcinomasMedical Oncology, 2015